Literature DB >> 11927612

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.

Alla Danilkovitch-Miagkova1, Berton Zbar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11927612      PMCID： PMC150937          DOI： 10.1172/JCI15418

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  34 in total

1.  Different point mutations in the met oncogene elicit distinct biological properties.

Authors:  S Giordano; A Maffe; T A Williams; S Artigiani; P Gual; A Bardelli; C Basilico; P Michieli; P M Comoglio
Journal:  FASEB J       Date:  2000-02       Impact factor: 5.191

2.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity.

Authors:  D Rusciano; P Lorenzoni; M M Burger
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

4.  Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44.

Authors:  D M Kamikura; H Khoury; C Maroun; M A Naujokas; M Park
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

5.  Cross-talk between the proto-oncogenes Met and Ron.

Authors:  A Follenzi; S Bakovic; P Gual; M C Stella; P Longati; P M Comoglio
Journal:  Oncogene       Date:  2000-06-22       Impact factor: 9.867

6.  Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src.

Authors:  N Nakaigawa; G Weirich; L Schmidt; B Zbar
Journal:  Oncogene       Date:  2000-06-15       Impact factor: 9.867

7.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.

Authors:  M F Di Renzo; M Olivero; T Martone; A Maffe; P Maggiora; A D Stefani; G Valente; S Giordano; G Cortesina; P M Comoglio
Journal:  Oncogene       Date:  2000-03-16       Impact factor: 9.867

8.  A novel germ line juxtamembrane Met mutation in human gastric cancer.

Authors:  J H Lee; S U Han; H Cho; B Jennings; B Gerrard; M Dean; L Schmidt; B Zbar; G F Vande Woude
Journal:  Oncogene       Date:  2000-10-12       Impact factor: 9.867

9.  Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.

Authors:  M Jo; D B Stolz; J E Esplen; K Dorko; G K Michalopoulos; S C Strom
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

10.  Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

Authors:  A Bardelli; P Longati; D Gramaglia; C Basilico; L Tamagnone; S Giordano; D Ballinari; P Michieli; P M Comoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205
View more
  96 in total

Review 1.  Invasive growth: from development to metastasis.

Authors:  Paolo M Comoglio; Livio Trusolino
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 2.  Integrins in invasive growth.

Authors:  Cord Brakebusch; Daniel Bouvard; Fabio Stanchi; Takao Sakai; Reinhard Fässler
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

3.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

4.  Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.

Authors:  Yao Dai; Kyungmi Bae; Christine Pampo; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2012-03       Impact factor: 5.150

5.  Negative feedback regulation of Met-dependent invasive growth by Notch.

Authors:  M Cristina Stella; Livio Trusolino; Selma Pennacchietti; Paolo M Comoglio
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

6.  C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.

Authors:  Vikas Bhardwaj; Yanai Zhan; Maria Angelica Cortez; Kie Kian Ang; David Molkentine; Anupama Munshi; Uma Raju; Ritsuko Komaki; John V Heymach; James Welsh
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

Review 7.  Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Authors:  Gulten Tuncel; Rasime Kalkan
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

8.  Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer.

Authors:  Woo Sung Moon; Ho Sung Park; Ho Lee; Rama Pai; Andrzej S Tarnawski; Kyung Ryoul Kim; Kyu Yun Jang
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

9.  Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.

Authors:  Tobias Ach; Katharina Zeitler; Stephan Schwarz-Furlan; Katharina Baader; Abbas Agaimy; Christian Rohrmeier; Johannes Zenk; Martin Gosau; Torsten E Reichert; Gero Brockhoff; Tobias Ettl
Journal:  Virchows Arch       Date:  2012-12-15       Impact factor: 4.064

10.  Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.

Authors:  Nikolaus Schiering; Stefan Knapp; Marina Marconi; Maria M Flocco; Jean Cui; Rita Perego; Luisa Rusconi; Cinzia Cristiani
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-14       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.